News
AMRX
13.12
+2.26%
0.29
A Look At Amneal Pharmaceuticals (AMRX) Valuation After Its Entry Into The Complex Inhalation Market
Simply Wall St · 22h ago
AMNEAL PHARMA - LAUNCHES ALBUTEROL SULFATE AND BECLOMETHASONE DIPROPIONATE HFA INHALATION AEROSOLS IN U.S.
Reuters · 1d ago
Amneal announces U.S. launch of two respiratory metered-dose inhalation products
TipRanks · 1d ago
Weekly Report: what happened at AMRX last week (0406-0410)?
Weekly Report · 2d ago
Should Amneal’s New Generic Glaucoma Launch Shape How AMRX Investors View Its Specialty Strategy?
Simply Wall St · 4d ago
Is It Time To Reassess Amneal Pharmaceuticals (AMRX) After Its Strong Multi Year Share Price Run?
Simply Wall St · 5d ago
FOCUS-Patients scramble to find estrogen patches as shortage worsens after US FDA champions use
Reuters · 6d ago
3 of Wall Street’s Favorite Stocks We Steer Clear Of
Barchart · 04/08 02:38
Amneal to report first-quarter results and host webcast call
Reuters · 04/07 20:01
Weekly Report: what happened at AMRX last week (0330-0403)?
Weekly Report · 04/06 10:19
Weekly Report: what happened at AMRX last week (0323-0327)?
Weekly Report · 03/30 10:20
Amneal Pharmaceuticals announced annual stockholders meeting; FY2025 revenue rose 8%
Reuters · 03/25 20:17
AMNEAL PHARMA: NOT RECEIVED ANY ADVERSE EVENT REPORTS RELATED TO THIS RECALL
Reuters · 03/24 20:25
AMNEAL PHARMA: VOLUNTARILY RECALLING ONE LOT OF MAGNESIUM SULFATE IN WATER FOR INJECTION, USP, 4G/100ML, IV BAG, TO THE HOSPITAL LEVEL
Reuters · 03/24 20:25
Amneal recalls one lot of Magnesium Sulfate in Water for Injection 4 g/100 mL after tranexamic acid mix-up
Reuters · 03/24 20:23
Weekly Report: what happened at AMRX last week (0316-0320)?
Weekly Report · 03/23 10:16
How Amneal’s Margin-Focused 2026 Outlook and 2025 Results Could Impact Amneal Pharmaceuticals (AMRX) Investors
Simply Wall St · 03/20 02:08
A Look At Amneal Pharmaceuticals (AMRX) Valuation After Strong 2025 Results And 2026 Growth Guidance
Simply Wall St · 03/19 01:11
Barclays Sticks to Their Buy Rating for Amneal Pharmaceuticals (AMRX)
TipRanks · 03/18 07:36
Amneal Pharmaceuticals: Flattish 2026 Revenue Growth Aside, Stock Still Looks A Buy
Seeking Alpha · 03/16 19:09
More
Webull provides a variety of real-time AMRX stock news. You can receive the latest news about Amneal Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About AMRX
Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.